Search research articles
Contact Us
Filters
Showing results (301-310 of 384) with videos related to
Page
of 39
Sort By:
The New England Journal of Medicine
|
May 31, 2024
Asciminib in Newly Diagnosed Chronic Myeloid Leukemia
Andreas Hochhaus, Jianxiang Wang, Dong-Wook Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 3, 2009
Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial
Jane F Apperley, Jorge E Cortes, Dong-Wook Kim, et al.
Leukemia
|
July 18, 2021
Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202
Amy S Ruppert, Allison M Booth, Wei Ding, et al.
Blood
|
October 28, 2011
ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category
Klaus H Metzeler, Heiko Becker, Kati Maharry, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 1, 2012
Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia
Guido Marcucci, Klaus H Metzeler, Sebastian Schwind, et al.
Blood
|
May 6, 2010
Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study
Heiko Becker, Guido Marcucci, Kati Maharry, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 13, 2023
Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results
Naval G Daver, Paresh Vyas, Suman Kambhampati, et al.
Blood Advances
|
December 21, 2018
Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance)
Gail J Roboz, Sumithra J Mandrekar, Pinkal Desai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 16, 2003
Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
Bruce D Cheson, John M Bennett, Kenneth J Kopecky, et al.
Blood
|
November 30, 2016
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Döhner, Elihu Estey, David Grimwade, et al.
Page
of 39
Search research articles
Search
Showing results (301-310 of 384) with videos related to
Sort By:
Page
of 39
The New England Journal of Medicine
|
May 31, 2024
Asciminib in Newly Diagnosed Chronic Myeloid Leukemia
Andreas Hochhaus, Jianxiang Wang, Dong-Wook Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 3, 2009
Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial
Jane F Apperley, Jorge E Cortes, Dong-Wook Kim, et al.
Leukemia
|
July 18, 2021
Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202
Amy S Ruppert, Allison M Booth, Wei Ding, et al.
Blood
|
October 28, 2011
ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category
Klaus H Metzeler, Heiko Becker, Kati Maharry, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 1, 2012
Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia
Guido Marcucci, Klaus H Metzeler, Sebastian Schwind, et al.
Blood
|
May 6, 2010
Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study
Heiko Becker, Guido Marcucci, Kati Maharry, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 13, 2023
Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results
Naval G Daver, Paresh Vyas, Suman Kambhampati, et al.
Blood Advances
|
December 21, 2018
Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance)
Gail J Roboz, Sumithra J Mandrekar, Pinkal Desai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 16, 2003
Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
Bruce D Cheson, John M Bennett, Kenneth J Kopecky, et al.
Blood
|
November 30, 2016
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Döhner, Elihu Estey, David Grimwade, et al.
Page
of 39